SHUBHAM PANT to Receptor, ErbB-2
This is a "connection" page, showing publications SHUBHAM PANT has written about Receptor, ErbB-2.
Connection Strength
0.266
-
Discordance of HER2 Expression and/or Amplification on Repeat Testing. Mol Cancer Ther. 2023 Aug 01; 22(8):976-984.
Score: 0.115
-
Regarding HER2-Amplified Biliary Tract Cancer. Oncologist. 2021 09; 26(9):e1664.
Score: 0.099
-
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation. Cancer Chemother Pharmacol. 2023 08; 92(2):107-118.
Score: 0.028
-
Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid Tumors. Clin Cancer Res. 2021 03 01; 27(5):1247-1255.
Score: 0.024